Marc Ramis-Castelltort
Co-Founder and CEO at Senolytic Therapeutics and Rejuveron.
Marc is passionate about creating novel biomedical ventures. He is a co-founder at Rejuversen AG, Ninevah Therapeutics SL and Senolytic Therapeutics Inc. Currently, Marc is a Board member or strategic advisor at Ninevah Therapeutics, Retinset Therapeutics, Cyclomed, Gate2Brain, Cebiotex and Origen Ventures. He is a co-founder and Partner at Chasing Science, an early-stage biomedical venture builder.
Marc gained a DPhil in Biochemistry from the University of Oxford, a PDL executive degree at Harvard Business School, a M.Sc. in Chemical Engineering and a B.Sc. in Chemistry from IQS (Barcelona).
Visit website: https://www.crunchbase.com/person/marc-ramis-castelltort
See also: 
Rejuveron
- Company that develops and invests in drugs and technologies which prolong human lifespan.
Details last updated 17-Feb-2021
Marc Ramis-Castelltort is also referenced in the following:
Longevity Leaders World Congress 2021
04-May-2021 to 07-May-2021
The virtual event for leaders in longevity science, technology, business and finance organized by Longevity Leaders (LSX).
Marc Ramis-Castelltort News
Super summary of 3rd Annual Longevity Therapeutics Summit
Lifespan.io (LEAF) - 16-Feb-2021
More and more companies making greater and greater progress - 2021 could be an exciting year
Read more...
